Preclinical and pharmacological studies of AG284, a soluble HLA-DR2: Myelin basic protein peptide complex for the treatment of multiple sclerosis

CNS Drug Reviews

Volumn 4, Issue 3, 1998, Pages 225-246

  Spack, Edward G ^a,b   Wehner, Nancy G ^a   Winkelhake, Jeffrey L ^a  

^a GLAXOSMITHKLINE   (United States)

^b Megabios Corporation   (United States)

Author keywords

AG284; HLA; MHC; Multiple sclerosis; Pharmacology; Toxicology

Indexed keywords

AG 284; AUTOANTIGEN; BETA1A INTERFERON; CHOLINERGIC RECEPTOR; GLATIRAMER; HLA DR2 ANTIGEN; INTERFERON BETA SERINE; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGENICITY; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HLA SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; REVIEW;

EID: 0032426008     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00066.x     Document Type: Review

References (47)

1. Blascyzk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
2. Boggs JM, Chang N-H, Groundalkar A, Hashim GA. Stimulation of tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen presenting cells. Cell Immunol 1992;143:23-40.
3. Bond AP, Corlett L, Cumow SJ, Spack E, Willcox N, Newsom-Davis J. Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T-cell clone from a myasthenia gravis patient after engaging the T-cell receptor with three different ligands. J Neuroimmunol 1998;82:182-190.
4. Boggs JM, Chang NH, Groundalkar A, Hashim GA. Stimulation or tolerization of an anti-myelin basic protein T lymphocyte line with membrane fragments from antigen-presenting cells. Cell Immunol 1992;143:23-40.
5. Brock S, Gijbels K, Allegretta M, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996;379:343-346.
6. Claus R, Werner H, Schulze H, Walzel H, Friemel H. Are soluble monocyte-derived HLA class II molecules candidates for immunosuppressive activity? Immunol Lett 1990;26:203-210.
7. Critchfield JM, Lenardo MJ. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin Immunol Immunopathol 1995;75:13-19.
8. Croft M, Dubey C. Accessory molecule and costimulation requirements for CD4 T-cell responses. Crit Rev Immunol 1997;17:89-118.
9. Dresser DW. Specific inhibition of antibody production. I. Protein over-loading paralysis. Immunology 1962;5:161-168.
10. Fuji Y, Lindstrom J. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. J Immunol 1988;140:1830-1837.
11. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993;90:6586-6590.
12. Goodkin DE, Ransohoff RM, Rudick RA. Experimental therapies for multiple sclerosis: Current status. Clev Clinic J Med 1992;59:63-74.
13. Grosse-Wilde H, Blascyzk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tiss Antigens 1992;39:74-77.
14. Jendro MK, Gornzy JJ, Weyand CM. Structural and functional characterization of HLA-DR molecules circulating in serum. Autoimmunity 1991;8:289-296.
15. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T-cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302-319.
16. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CCA, Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis: Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993;92:2602-2608.
17. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-157.
18. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998;101:725-730.
19. Manning CH, Heise ER. Biochemical analysis of class I and class II MHC antigens in cynomolgus macaques by one-dimensional isoelectric focusing. Tiss Antigens 1991;37:56-65.
20. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990;145:540-548.
21. Miller A, Lider O, Roberts AB, Sporn M, Weiner HL. Suppressor T cells generated by oral tolerance to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigen specific triggering. Proc Natl Acad Sci USA 1992;89:421-425.
22. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution for five therapeutic proteins. Pharm Res 1991;8:1351-1359.
23. Nau GJ, Moldwin RL, Lancki DW, Kim D, Fitch FW. Inhibition of IL-2-driven proliferation of murine T-lymphocyte clones by supraoptimal levels of immobilized anti-T-cell receptor monoclonal antibody. J Immunol 1987;139:114-122.
24. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994;93:1361-1369.
25. Olerup O, Hillert J. HLA class II associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tiss Antigens 1991;38:1-15.
26. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
27. Ott M, Seidl C, Westhoff U, et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tiss Antigens 1998;51:301-304.
28. Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990;87:7968-7972.
29. Pette M, Fujita K, Kitze B, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990;40:1770-1776.
30. Quill H, Schwartz RH. Stimulation of normal inducer T-cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987;138:3704-3712.
31. Salvetti M, Ristori G, D'Amato M, et al. Predominant and stable T-cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis. Eur J Immunol 1993:23:1232-1239.
32. Schulz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998;160:1532-1538.
33. Schwartz RH. Models of T-cell anergy: is there a common molecular mechanism? J Exp Med 1996;184:1-8.
34. Sharma SD, Nag B, Su X-M, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci USA 1991;88:11465-11469.
35. Spack EG, McCutcheon M, Corbelletta N, Nag B, Passmore D, Sharma SD. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes. J Autoimmun 1995;8:787-807.
36. Spack EG. Induction of apoptosis in autoreactive T cells with soluble MHC II:peptide complexes. In: Hori, W., ed. Apoptosis: Practical applications and novel therapies. Southborough, MA: IBC's Library Series, 1997:2.4.1-2.4.26.
37. Spack EG. Drugs in development for the treatment of multiple sclerosis: Antigen-specific therapies. Exp Opin Invest Drugs 1996;5:1331-1348.
38. Spack EG. Antigen-specific therapies for the treatment of multiple sclerosis: A clinical trial update. Exp Opin Invest Drugs 1997;6: 1715-1727.
39. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc Natl Acad Sci USA 1996;93:2253-2256.
40. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-173.
41. Tiwari JL, Terasaki PI. HLA and disease associations. New York: Springer Verlag, 1985.
42. Trotter J, Sriram S, Rassenti L, Chou CH, Fritz RB, Steinman L. Characterization of T cell lines and clones from SJL/J and (BALB/c x SJL/J)F1 mice specific for myelin basic protein. J Immunol 1985;134:2322-2327.
43. Valli A, Sette A, Kappos L, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993;91:616-628.
44. Varma RK, Kaushal R, Junnarkar AY, et al. Polysorbate 80: A pharmacological study. Drug Res 1985;35:804-808.
45. Webb S, Sprent J. Downregulation of T-cell responses by antibodies to the T-cell receptor. J Exp Med 1987;165:584-589.
46. Weyand CM, Jendro M, Goronzy JJ. Soluble HLA-DR molecules in patients with HLA class II versus class I associated disorders. Autoimmunology 1991;8:281-287.
47. Wucherpfenig KW, Zhang J, Witek C, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-5592.